ArriVent BioPharma (AVBP) Change in Account Payables (2023 - 2026)
ArriVent BioPharma (AVBP) reported Change in Account Payables of $2.8 million for Q1 2026, up 382.3% on a YoY basis from $582000.0 in Q1 2025, and up 35187.5% sequentially from -$8000.0 in Q4 2025.
ArriVent BioPharma (AVBP) Change in Account Payables (2023 - 2026) Analysis & Trends
ArriVent BioPharma (AVBP) has 4 years of Change in Account Payables data on file, last reported at $2.8 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables rose 382.3% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $4.4 million (up 2029.76% YoY), and the FY2025 full-year result was $2.1 million, up 385.09% from the prior year.
- Change in Account Payables advanced to $2.8 million in Q1 2026, from -$8000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $3.7 million in Q2 2023 to a low of -$2.2 million in Q3 2023.
- A 4-year average of $428923.1 and a median of -$8000.0 in 2025 frame the typical range for Change in Account Payables.
- Across the five-year window, Change in Account Payables tumbled 393.22% in 2024 and jumped 382.3% in 2026, its largest moves.
- Tracing AVBP's Change in Account Payables over 4 years: stood at $295000.0 in 2023, then plunged by 393.22% to -$865000.0 in 2024, then soared by 99.08% to -$8000.0 in 2025, then jumped by 35187.5% to $2.8 million in 2026.
- Business Quant data shows AVBP's Change in Account Payables at $2.8 million in Q1 2026, -$8000.0 in Q4 2025, and $1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | ArriVent BioPharma | 1.42 Bn | 1.42 Bn | - | 2.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.81 Mn |
| Mar 31, 2026 | 2.81 Mn |
| Dec 31, 2025 | -8,000.00 |
| Dec 31, 2025 | -8,000.00 |
| Sep 30, 2025 | 1.87 Mn |
| Sep 30, 2025 | 1.87 Mn |
| Jun 30, 2025 | -302,000.00 |
| Jun 30, 2025 | -302,000.00 |
| Mar 31, 2025 | 582,000.00 |
| Mar 31, 2025 | 582,000.00 |
| Dec 31, 2024 | -865,000.00 |
| Dec 31, 2024 | -865,000.00 |
| Sep 30, 2024 | 834,000.00 |
| Sep 30, 2024 | 834,000.00 |
| Jun 30, 2024 | -346,000.00 |
| Jun 30, 2024 | -346,000.00 |
| Mar 31, 2024 | -374,000.00 |
| Mar 31, 2024 | -374,000.00 |
| Dec 31, 2023 | 295,000.00 |
| Dec 31, 2023 | 295,000.00 |